Real-World Delivery, Dose Adaptation, and Molecular Monitoring of Gilteritinib, Venetoclax, and Azacitidine in Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia
Real-World Delivery, Dose Adaptation, and Molecular Monitoring of Gilteritinib, Venetoclax, and Azacitidine in Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia. // Clinical Lymphoma, Myeloma & Leukemia. – URL: https://www.sciencedirect.com/science/article/pii/S2152265026002405?dgcid=rss_sd_all
Real-World Delivery, Dose Adaptation, and Molecular Monitoring of Gilteritinib, Venetoclax, and Azacitidine in Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma & Leukemia. https://www.sciencedirect.com/science/article/pii/S2152265026002405?dgcid=rss_sd_all
“Real-World Delivery, Dose Adaptation, and Molecular Monitoring of Gilteritinib, Venetoclax, and Azacitidine in Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia.” Clinical Lymphoma, Myeloma & Leukemia.
@article{article93536,
title = {Real-World Delivery, Dose Adaptation, and Molecular Monitoring of Gilteritinib, Venetoclax, and Azacitidine in Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia},
journal = {Clinical Lymphoma, Myeloma \& Leukemia},
url = {https://www.sciencedirect.com/science/article/pii/S2152265026002405?dgcid=rss_sd_all}
}